Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report issued on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Several other equities research analysts also recently issued reports on the company. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. HC Wainwright restated a “neutral” rating and issued a $2.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $4.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Jefferies Financial Group reissued a “hold” rating and set a $0.50 price objective (down from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Finally, Truist Financial lowered shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of MRNS stock opened at $0.54 on Tuesday. The company’s fifty day moving average price is $0.37 and its two-hundred day moving average price is $0.99. The firm has a market capitalization of $29.81 million, a P/E ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 12 month low of $0.22 and a 12 month high of $10.50.

Institutional Investors Weigh In On Marinus Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Point72 DIFC Ltd bought a new position in Marinus Pharmaceuticals in the second quarter worth about $28,000. AQR Capital Management LLC boosted its holdings in shares of Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 12,934 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in Marinus Pharmaceuticals during the 2nd quarter valued at about $64,000. World Investment Advisors LLC bought a new position in Marinus Pharmaceuticals in the 3rd quarter worth approximately $104,000. Finally, JPMorgan Chase & Co. grew its stake in shares of Marinus Pharmaceuticals by 1,968.5% in the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 126,752 shares in the last quarter. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.